These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 10912316)

  • 21. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
    Teo KK; Mitchell LB; Pogue J; Bosch J; Dagenais G; Yusuf S;
    Circulation; 2004 Sep; 110(11):1413-7. PubMed ID: 15353497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).
    Kjøller-Hansen L; Steffensen R; Grande P
    Am Heart J; 2004 Sep; 148(3):475-80. PubMed ID: 15389235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HOPE study: comparison with other trials of secondary prevention.
    Otterstad JE; Sleight P
    Eur Heart J; 2001 Aug; 22(15):1307-10. PubMed ID: 11465962
    [No Abstract]   [Full Text] [Related]  

  • 24. Angiotensin converting enzyme inhibitor therapy.
    Róna G
    Ther Hung; 1991; 39(2):63-70. PubMed ID: 1948779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of ramipril on the circadian periodicity of acute myocardial infarction.
    Dagenais GR; Pogue J; Teo KK; Lonn EM; Yusuf S;
    Am J Cardiol; 2006 Sep; 98(6):758-60. PubMed ID: 16950179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [What is the purpose of dual or triple inhibition of the renin-angiotensin-aldosterone system?].
    Legrand D; Krzesinski JM; Scheen AJ
    Rev Med Suisse; 2008 Aug; 4(168):1792-7. PubMed ID: 18814762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ramipril: a review of its use in the prevention of cardiovascular outcomes.
    Warner GT; Perry CM
    Drugs; 2002; 62(9):1381-405. PubMed ID: 12076194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of ACE inhibitor therapy in treating cardiovascular disease.
    Flint L
    Nurs Times; 2004 Mar 23-29; 100(12):34-7. PubMed ID: 15067910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experiences with the realisation of innovative study designs using the example of the HOPE-study].
    Rangoonwala B
    Dtsch Med Wochenschr; 2005 Jul; 130 Suppl 2():S82-5. PubMed ID: 15988674
    [No Abstract]   [Full Text] [Related]  

  • 30. Ramipril for the prevention and treatment of cardiovascular disease.
    Vuong AD; Annis LG
    Ann Pharmacother; 2003 Mar; 37(3):412-9. PubMed ID: 12639174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The HOPE Study. What does it contribute to general practice?].
    Mann J; Sleight P
    MMW Fortschr Med; 2000 Nov; 142(47):28-32. PubMed ID: 11143776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
    Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACE inhibitors: review of four new agents.
    Binder SB
    Am Fam Physician; 1993 Oct; 48(5):851-7. PubMed ID: 8213415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future perspectives and implications.
    Sleight P
    Int J Clin Pract Suppl; 2001 Jan; (117):22-3. PubMed ID: 11715355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The efficacy of treatment with the angiotensin-converting enzyme inhibitor ramipril in patients with congestive heart failure of rheumatic etiology].
    Karakin AA; Khrustalev OA; Bol'shakova MA; Forsilov VE
    Ter Arkh; 1996; 68(2):43-6. PubMed ID: 8771657
    [No Abstract]   [Full Text] [Related]  

  • 36. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials.
    Bertrand ME
    Curr Med Res Opin; 2004 Oct; 20(10):1559-69. PubMed ID: 15462689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spotlight on ramipril in the prevention of cardiovascular outcomes.
    Warner GT; Perry CM
    Am J Cardiovasc Drugs; 2003; 3(2):113-6. PubMed ID: 14727938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
    ; Yusuf S; Sleight P; Pogue J; Bosch J; Davies R; Dagenais G
    N Engl J Med; 2000 Jan; 342(3):145-53. PubMed ID: 10639539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of the angiotensin-converting enzyme inhibitor ramipril on the processes of lipid peroxidation on the status of the endogenous antioxidant system in patients with myocardial infarction].
    Davydov BV; Golikov PP; Marchenko VV; Riabinin VA; Golikov AP
    Patol Fiziol Eksp Ter; 1997; (4):3-5. PubMed ID: 9471600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.